HormonesResearch PaperPaywall

p16 Plays a Double Role in Endometriosis, Linking Cell Senescence to Persistent Disease

A narrative review argues p16 acts as a context-dependent switch in endometriosis, and that early mTOR-targeted senescence suppression may be worth exploring.

Wednesday, November 18, 2026 0 views
Published in Reprod Sci
gynecologist reviewing a pelvic ultrasound image on a monitor with a woman patient in a clinic exam room

Summary

Endometriosis is an estrogen-driven disease that causes chronic inflammation, scarring, pelvic pain and infertility. This review looks at p16, a protein best known as a marker of senescent (aged, growth-arrested) cells. The author argues that endometriotic lesions contain two kinds of cells. Cells with high p16 look senescent and are tied to inflammation, immune suppression and abnormal tissue remodeling. Cells with low p16 can keep dividing through CDK4/6 activity and appear to survive well, partly because they depend less on inflammatory senescence signals. So p16 may act as a context-dependent regulator rather than a simple brake on growth. The review also notes early evidence that indirectly targeting mTOR signaling may lower p16/p21 and senescence-associated secretion. The author suggests treatment should aim to stop senescence before it becomes irreversible and restore a healthy endometrial environment, rather than just adjusting p16. This is a narrative review of existing studies, not new data, and it proposes a framework rather than a proven therapy.

Detailed Summary

Endometriosis affects many women and drives chronic pelvic pain and infertility. It is estrogen-dependent, inflammatory and fibrotic, and current treatments mostly suppress hormones rather than address the tissue biology that keeps lesions going. Senescence biology, a core topic in aging research, may offer a new angle.

This narrative review examines p16INK4a, a canonical senescence marker, in endometriosis. Its expression is dysregulated in lesions, and, paradoxically, that change has been linked to disease persistence even though p16 normally suppresses proliferation. The author surveyed basic and clinical literature on endometriosis, endometrial biology, senescence, p16, the senescence-associated secretory phenotype (SASP), immune regulation and senotherapeutics.

The central conclusion is that lesions contain distinct high-p16 and low-p16 cell populations. High p16 is associated with senescence, chronic inflammation, an immunosuppressive microenvironment and aberrant tissue remodeling. Low p16 may preserve proliferative capacity through CDK4/6 activity and sustain a survival-advantaged, plastic state, partly because the cells rely less on SASP. On this view p16 links senescence, inflammation and tissue plasticity depending on context.

For therapy, the review reports emerging evidence that indirect mTOR-targeting interventions may attenuate p16/p21 expression and SASP. The author argues that treatment should not simply push p16 up or down. It should suppress senescence before it becomes irreversible and restore a functional endometrial environment. This ties endometriosis to the senotherapeutic and mTOR concepts familiar from longevity research.

Caveats matter. This is a narrative review, not a systematic one, so study selection may be biased. It generates a conceptual framework and does not test it. No human trial results for senotherapeutics in endometriosis are described in the abstract, and the mTOR evidence is called emerging. Only the abstract was available for this summary.

Key Findings

  • Endometriotic lesions contain distinct high-p16 and low-p16 cell populations, per this narrative review of existing literature.
  • High p16 is linked to senescence, chronic inflammation, immunosuppressive microenvironment and abnormal tissue remodeling.
  • Low p16 may sustain proliferation through CDK4/6 activity and a survival-advantaged, plastic state with less SASP dependence.
  • Emerging evidence suggests indirect mTOR targeting may lower p16/p21 and SASP; no clinical outcomes are reported in the abstract.

Methodology

Narrative review of basic and clinical studies on endometriosis, endometrial biology, senescence, p16, SASP, immune regulation and senotherapeutics. No systematic search, pooling or quality grading is described in the abstract. Evidence level is mechanistic and conceptual.

Study Limitations

The summary is based on the abstract only, so details of the included studies are unavailable. Narrative reviews can reflect author selection bias, and the abstract reports no functional, symptom or fertility outcomes for any intervention. The mTOR evidence is described as emerging and indirect, and the model systems and species behind it are not stated.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: